Eleven diabetes patients have filed a lawsuit in a federal court in Massachusetts accusing three big pharmaceutical companies of inflating the prices of lifesaving drugs by 150 percent and harming patients in the process.
Diabetes sufferers, who need daily doses of insulin to survive, watched as Sanofi, Novo Nordisk and Eli Lilly jacked up the price of insulin from $25 per prescription to as much $300-400 over five years, according to the complaint filed Monday.
Drug manufacturers usually rationalize drug price increases by claiming the high costs of research and development. In this instance, the plaintiffs claim, manufacturers admitted their price hikes were neither related to such costs nor any jump in production expenses.
The suit referred to a February 2016 op-ed written by an endocrinologist in the New York Times, which revealed the price hike had nothing to do with production costs.
The lawsuit cites examples of how the opaque drug-pricing system left many people unable to afford their insulin treatment, which can cost some patients up to $900 a month.
Full Content: RT
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Landmark Monopoly Trial Between DOJ and Google Wraps Up
May 2, 2024 by
CPI
Lawmaker Probes FTC and EU’s Role in Amazon’s Failed iRobot Acquisition
May 2, 2024 by
CPI
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Healthcare Pricing
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI